Biomarkers in Samples From Young Patients With Neuroblastoma
NCT ID: NCT01358604
Last Updated: 2016-04-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
20 participants
OBSERVATIONAL
2011-05-31
2016-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This research study studies biomarkers in samples from young patients with neuroblastoma.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Biomarkers in Young Patients With Neuroblastoma
NCT01169376
Prognostic Biomarkers in Tumor Tissue Samples From Young Patients With Neuroblastoma
NCT01358617
Studying Gene Expression in Samples From Younger Patients With Neuroblastoma
NCT01553448
Biomarkers in Tumor Samples From Younger Patients With Neuroblastoma
NCT01493830
Biomarkers in Blood and Tissue Samples From Patients With Newly Diagnosed Neuroblastoma
NCT01387724
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Primary
* To analyze the expression of ROR1 on the surface of primary neuroblastoma cells.
* To investigate the therapeutic potential of anti-ROR1 monoclonal antibodies (mAbs), bispecific antibodies, and immunotoxins in in vitro and in vivo models of neuroblastoma.
OUTLINE: Archived bone marrow and tumor tissue samples are analyzed for ROR1 expression by flow cytometry, western blotting, qPCR, and IHC.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
polymerase chain reaction
protein expression analysis
western blotting
flow cytometry
immunohistochemistry staining method
laboratory biomarker analysis
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosed with neuroblastoma
* With or without N-myc amplification
* Primary tumor samples as frozen tissue in liquid nitrogen or -80 degrees C
* Bone marrow samples from high-risk patients as peripheral blood mononuclear cells (PBMC) that have been cryopreserved with DMSO as viable cells to be used for flow cytometry or slides of bone marrow that can be used for immunohistochemistry
PATIENT CHARACTERISTICS:
* Not specified
PRIOR CONCURRENT THERAPY:
* Not specified
120 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Children's Oncology Group
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
David Hema, MD, MPH
Role: PRINCIPAL_INVESTIGATOR
NCI - Experimental Transplantation and Immunology Branch
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
COG-ANBL11B2
Identifier Type: OTHER
Identifier Source: secondary_id
NCI-2011-02855
Identifier Type: REGISTRY
Identifier Source: secondary_id
ANBL11B2
Identifier Type: OTHER
Identifier Source: secondary_id
ANBL11B2
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.